Treatment of lower urinary tract symptoms in men in primary care using a conservative intervention: cluster randomised controlled trial
Treatment of lower urinary tract symptoms in men in primary care using a conservative intervention: cluster randomised controlled trial
Objective: To determine whether a standardised and manualised care intervention in men in primary care could achieve superior improvement of lower urinary tract symptoms (LUTS) compared with usual care. Design: Cluster randomised controlled trial. Setting: 30 National Health Service general practice sites in England. Participants: Sites were randomised 1:1 to the intervention and control arms. 1077 men (≥18 years) with bothersome LUTS recruited between June 2018 and August 2019: 524 were assigned to the intervention arm (n=17 sites) and 553 were assigned to the usual care arm (n=13 sites). Intervention: Standardised information booklet developed with patient and expert input, providing guidance on conservative and lifestyle interventions for LUTS in men. After assessment of urinary symptoms (manualised element), general practice nurses and healthcare assistants or research nurses directed participants to relevant sections of the manual and provided contact over 12 weeks to assist with adherence. Main outcome measures: The primary outcome was patient reported International Prostate Symptom Score (IPSS) measured 12 months after participants had consented to take part in the study. The target reduction of 2.0 points on which the study was powered reflects the minimal clinically important difference where baseline IPSS is <20. Secondary outcomes were patient reported quality of life, urinary symptoms and perception of LUTS, hospital referrals, and adverse events. The primary intention-to-treat analysis included 887 participants (82% of those recruited) and used a mixed effects multilevel linear regression model adjusted for site level variables used in the randomisation and baseline scores. Results: Participants in the intervention arm had a lower mean IPSS at 12 months (adjusted mean difference -1.81 points, 95% confidence interval -2.66 to -0.95) indicating less severe urinary symptoms than those in the usual care arm. LUTS specific quality of life, incontinence, and perception of LUTS also improved more in the intervention arm than usual care arm at 12 months. The proportion of urology referrals (intervention 7.3%, usual care 7.9%) and adverse events (intervention seven events, usual care eight events) were comparable between the arms. Conclusions: A standardised and manualised intervention in primary care showed a sustained reduction in LUTS in men at 12 months. The mean difference of -1.81 points (95% confidence interval -0.95 to -2.66) on the IPSS was less than the predefined target reduction of 2.0 points. Trial registration: ISRCTN Registry ISRCTN11669964.
Drake, Marcus J.
60d630c3-0d89-4513-94b6-72671bd28b94
Worthington, Jo
a22547a2-46b8-4948-b64f-24d7f614eb3b
Frost, Jessica
4f9b2164-3345-48b4-b170-698c79465aad
Sanderson, Emily
7ff83f79-110b-415b-85d2-ba4346630008
Cochrane, Madeleine
11996c99-26d9-4636-9cfa-2d0e071c13ee
Cotterill, Nikki
c0ef5dfc-a9ae-4ebb-a3ed-5afb7805ff92
Fader, Mandy
c318f942-2ddb-462a-9183-8b678faf7277
McGeagh, Lucy
6eba6245-776e-445c-a1f9-d31ca01adde5
Hashim, Hashim
837f6d30-3735-4fc3-b6ed-0148b7c0ea90
Macaulay, Margaret
505970d3-1e67-4c1f-8291-3a950d336c6b
Rees, Jonathan
8a58a967-d239-4300-b363-ca471bf7047f
Robles, Luke A.
5fc2d2ac-7f24-4ced-a845-63ff5a23ef0b
Taylor, Gordon
d2545be0-964b-4e5a-99cb-ec89831f88fc
Taylor, Jodi
875cc40a-d428-4a7d-9ee0-710051549a88
Ridd, Matthew J.
de8b7ad0-5afa-4231-99f6-d6778744ddd4
MacNeill, Stephanie J.
2c5c4027-4f93-4cc8-a56c-fa85772f3a09
Noble, Sian
0d4178fd-a7e7-408c-af04-3e30e09d1559
Lane, J. Athene
6683aef1-075d-471f-9c9f-b561a2a3902e
15 November 2023
Drake, Marcus J.
60d630c3-0d89-4513-94b6-72671bd28b94
Worthington, Jo
a22547a2-46b8-4948-b64f-24d7f614eb3b
Frost, Jessica
4f9b2164-3345-48b4-b170-698c79465aad
Sanderson, Emily
7ff83f79-110b-415b-85d2-ba4346630008
Cochrane, Madeleine
11996c99-26d9-4636-9cfa-2d0e071c13ee
Cotterill, Nikki
c0ef5dfc-a9ae-4ebb-a3ed-5afb7805ff92
Fader, Mandy
c318f942-2ddb-462a-9183-8b678faf7277
McGeagh, Lucy
6eba6245-776e-445c-a1f9-d31ca01adde5
Hashim, Hashim
837f6d30-3735-4fc3-b6ed-0148b7c0ea90
Macaulay, Margaret
505970d3-1e67-4c1f-8291-3a950d336c6b
Rees, Jonathan
8a58a967-d239-4300-b363-ca471bf7047f
Robles, Luke A.
5fc2d2ac-7f24-4ced-a845-63ff5a23ef0b
Taylor, Gordon
d2545be0-964b-4e5a-99cb-ec89831f88fc
Taylor, Jodi
875cc40a-d428-4a7d-9ee0-710051549a88
Ridd, Matthew J.
de8b7ad0-5afa-4231-99f6-d6778744ddd4
MacNeill, Stephanie J.
2c5c4027-4f93-4cc8-a56c-fa85772f3a09
Noble, Sian
0d4178fd-a7e7-408c-af04-3e30e09d1559
Lane, J. Athene
6683aef1-075d-471f-9c9f-b561a2a3902e
Drake, Marcus J., Worthington, Jo, Frost, Jessica, Sanderson, Emily, Cochrane, Madeleine, Cotterill, Nikki, Fader, Mandy, McGeagh, Lucy, Hashim, Hashim, Macaulay, Margaret, Rees, Jonathan, Robles, Luke A., Taylor, Gordon, Taylor, Jodi, Ridd, Matthew J., MacNeill, Stephanie J., Noble, Sian and Lane, J. Athene
(2023)
Treatment of lower urinary tract symptoms in men in primary care using a conservative intervention: cluster randomised controlled trial.
BMJ, [e075219].
(doi:10.1136/bmj-2023-075219).
Abstract
Objective: To determine whether a standardised and manualised care intervention in men in primary care could achieve superior improvement of lower urinary tract symptoms (LUTS) compared with usual care. Design: Cluster randomised controlled trial. Setting: 30 National Health Service general practice sites in England. Participants: Sites were randomised 1:1 to the intervention and control arms. 1077 men (≥18 years) with bothersome LUTS recruited between June 2018 and August 2019: 524 were assigned to the intervention arm (n=17 sites) and 553 were assigned to the usual care arm (n=13 sites). Intervention: Standardised information booklet developed with patient and expert input, providing guidance on conservative and lifestyle interventions for LUTS in men. After assessment of urinary symptoms (manualised element), general practice nurses and healthcare assistants or research nurses directed participants to relevant sections of the manual and provided contact over 12 weeks to assist with adherence. Main outcome measures: The primary outcome was patient reported International Prostate Symptom Score (IPSS) measured 12 months after participants had consented to take part in the study. The target reduction of 2.0 points on which the study was powered reflects the minimal clinically important difference where baseline IPSS is <20. Secondary outcomes were patient reported quality of life, urinary symptoms and perception of LUTS, hospital referrals, and adverse events. The primary intention-to-treat analysis included 887 participants (82% of those recruited) and used a mixed effects multilevel linear regression model adjusted for site level variables used in the randomisation and baseline scores. Results: Participants in the intervention arm had a lower mean IPSS at 12 months (adjusted mean difference -1.81 points, 95% confidence interval -2.66 to -0.95) indicating less severe urinary symptoms than those in the usual care arm. LUTS specific quality of life, incontinence, and perception of LUTS also improved more in the intervention arm than usual care arm at 12 months. The proportion of urology referrals (intervention 7.3%, usual care 7.9%) and adverse events (intervention seven events, usual care eight events) were comparable between the arms. Conclusions: A standardised and manualised intervention in primary care showed a sustained reduction in LUTS in men at 12 months. The mean difference of -1.81 points (95% confidence interval -0.95 to -2.66) on the IPSS was less than the predefined target reduction of 2.0 points. Trial registration: ISRCTN Registry ISRCTN11669964.
Text
BMJ-2023-075219.R3_Accepted_02.10.23 (no booklet)
- Accepted Manuscript
Text
bmj-2023-075219.full
- Version of Record
More information
Accepted/In Press date: 2 October 2023
e-pub ahead of print date: 15 November 2023
Published date: 15 November 2023
Additional Information:
Funding Information:
Funding: This study was funded by the National Institute for Health and Care Research (NIHR, formerly the National Institute of Health Research), Health Technology Assessment programme (No 16/90/03). The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, NIHR or Department of Health and Social Care. MJR was partially funded by a postdoctoral research fellowship from the NIHR (PDF-2014-07-013) from the start of the study until 31 December 2019. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Funding Information:
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the UK National Institute for Health and Care Research Health Technology Assessment (HTA) programme for the submitted work; MJD reports personal fees from Astellas and Pfizer, outside the submitted work. JR is chair of the Primary Care Urology Society, which has received non-promotional sponsorship for annual meetings from Ferring, Astellas, Neotract, and IMedicare. He has also received speaker fees from Astellas Pharmaceuticals. HH reports personal fees from Medtronic, Astellas, Allergan, and Boston Scientific, outside the submitted work. JAL reports receiving funding for the clinical trials unit (CTU) of which she was codirector, and she was a member on the National Institute for Health and Care Research (NIHR) CTU Standing Advisory Committee. MJR has been on several NIHR committees, including the Systematic Reviews NIHR Cochrane Incentive Awards, HTA General Committee, Evidence Synthesis Programme Grants Committee, and NIHR Incentive Awards Committee, and is currently on the Evidence Synthesis Programme Advisory Group. SJM is an active member of the HTA General Committee.
Publisher Copyright:
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.
Identifiers
Local EPrints ID: 485837
URI: http://eprints.soton.ac.uk/id/eprint/485837
ISSN: 0959-8138
PURE UUID: 70dd402f-2311-442e-8903-dd5d18bf1901
Catalogue record
Date deposited: 20 Dec 2023 17:34
Last modified: 06 Jun 2024 02:00
Export record
Altmetrics
Contributors
Author:
Marcus J. Drake
Author:
Jo Worthington
Author:
Jessica Frost
Author:
Emily Sanderson
Author:
Madeleine Cochrane
Author:
Nikki Cotterill
Author:
Lucy McGeagh
Author:
Hashim Hashim
Author:
Jonathan Rees
Author:
Luke A. Robles
Author:
Gordon Taylor
Author:
Jodi Taylor
Author:
Matthew J. Ridd
Author:
Stephanie J. MacNeill
Author:
Sian Noble
Author:
J. Athene Lane
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics